Skip to main content
Article thumbnail
Location of Repository

Ustekinumab significantly improves physical function and health-related quality of life in patients with psoriatic arthritis

By Proton Rahman, Lluis Puig, Alice B. Gottlieb, Arthur Kavanaugh, Iain B. McInnes, Christopher Ritchlin, Shu Li, Yuhua Wang, Michael Song, Alan Mendelsohn and Chenglong Han

Abstract

Objective: Examine ustekinumab effects on patient-reported outcomes (PROs) in PSUMMIT-1/PSUMMIT-2 patients with active psoriatic arthritis (PsA) who were methotrexate (MTX)-naïve, MTX-experienced, or anti-tumor necrosis factor (TNF)-experienced.\ud \ud Methods: Patients in the Phase 3, PSUMMIT 1 (n=615) and PSUMMIT 2 (n=312) studies randomly (1:1:1) received placebo, ustekinumab 45 mg, or ustekinumab 90 mg subcutaneous injections at wk0/wk4/wk16/wk28/wk40/wk52. PROs (Health Assessment Questionnaire-Disability Index [HAQ-DI]; Dermatology Life Quality index [DLQI]; 36-item short-form health survey physical and mental component summary [SF-36 PCS/MCS] scores; patient assessments of pain and disease activity; impact of disease on productivity) were assessed at wk0/wk24/wk52. In these post-hoc analyses, outcomes were compared between the ustekinumab and placebo groups for three mutually-exclusive antecedent-exposure populations from the combined studies: MTX/anti-TNF naïve (placebo, n=56; 45 mg, n=58; 90 mg, n=66), MTX-experienced, bio-naive (placebo, n=192; 45 mg, n=190; 90 mg, n=185), and anti-TNF experienced with or without MTX (placebo, n=62; 45 mg, n=60, 90 mg, n=58).\ud \ud Results: At wk24, mean improvements from baseline in HAQ-DI, DLQI, and SF-36 PCS scores were significantly greater in both ustekinumab groups versus placebo across antecedent-exposure groups. Greater proportions of ustekinumab- than placebo-treated patients (all p<0.05) had clinically meaningful improvements in HAQ-DI (≥0.3), DLQI (≥5), and SF-36 (≥5) scores at wk24, irrespective of drug exposure. Improvements in pain, disease activity, and impact of disease on productivity were similar, and benefits were maintained through wk52.\ud \ud Conclusions: Significant improvements in PROs with ustekinumab vs. placebo were observed in three antecedent-exposure populations of PsA patients, including those with prior MTX and anti-TNF use

Publisher: Wiley
Year: 2016
OAI identifier: oai:eprints.gla.ac.uk:122689
Provided by: Enlighten

Suggested articles


To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.